Anthrasil Liquid
NDC Package 60492-0249-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Anthrasil (anthrax immune globulin (human)) liquids is aNTHRASIL is an Anthrax Immune Globulin Intravenous (Human) indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs. This formulation utilizes a liquid delivery system. Marketed by Emergent Biosolutions Canada Inc., this product is identified by NDC 60492-0249 and is authorized under FDA application BLA125562.

Identification & Billing

NDC Package Code
60492-0249-2
Package Description
7 VIAL in 1 CARTON / 35 mL in 1 VIAL (60492-0249-1)
Product Code
60492-0249
11-Digit Billing Format
60492024902
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Anthrasil
Non-Proprietary Name
Anthrax Immune Globulin (human)
Substance Name
Anthrax Immune Globulin Human
Dosage Form
Liquid - A dosage form consisting of a pure chemical in its liquid1 state. This dosage form term should not be applied to solutions.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
ANTHRAX IMMUNE GLOBULIN HUMAN 60 [iU]/35mL
Usage Information
ANTHRASIL is an Anthrax Immune Globulin Intravenous (Human) indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs. The effectiveness of ANTHRASIL is based solely on efficacy studies conducted in animal models of inhalational anthrax [See 13.2 Animal Toxicology and/or Pharmacology].Limitations:•ANTHRASIL does not have direct antibacterial activity.•ANTHRASIL does not cross the blood-brain barrier and does not prevent or treat meningitis.•There have been no studies of ANTHRASIL in the pediatric, geriatric, or obese populations.

Regulatory & Marketing

Labeler Name
Emergent Biosolutions Canada Inc.
Product Type
Plasma Derivative
FDA Application #
BLA125562
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
10-05-2015
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 60492-0249-2 identifies a specific commercial package of 7 vial in 1 carton / 35 ml in 1 vial (60492-0249-1) of Anthrasil, a plasma derivative labeled by Emergent Biosolutions Canada Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This liquid is formulated for intravenous use and contains anthrax immune globulin human as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Emergent Biosolutions Canada Inc. on October 05, 2015. The current certification is valid through December 31, 2027.

How is this Emergent Biosolutions Canada Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 60492024902. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
60492-0249-2
11-Digit CMS (5-4-2)
60492-0249-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.